Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced non-small-cell lung cancer
10.3760/cma.j.issn.1673-422X.2010.03.016
- VernacularTitle:非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂的一线治疗
- Author:
Jin YANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Receptor,epidermal growth factor;
Protein-tyrosine kinases;
Enzyme inhibitors
- From:
Journal of International Oncology
2010;37(3):210-213
- CountryChina
- Language:Chinese
-
Abstract:
Several models about epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)as first-line treatment in advanced NSCLC show different results.Combination with chemotherapy and EG-FR-TKIs did not indicate survival advantage.However,sequential chemotherapy in EGFR-TKIs and a single agent of EGFR-TKIs as first-line treatment of advanced NSCLC have made tremendous breakthrough,and give a new path in individual treatment of advanced NSCLC.Also EGFR mulatious in targeted therapy of advanced NSCLc has a sood predictive value of the etticacy.
